Starling Oncology Institute Inc (STLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 161,282 | 147,441 | 141,957 | 136,564 | 119,802 |
| Cost of Goods | 134,117 | 124,126 | 119,192 | 117,644 | 102,301 |
| Gross Profit | 27,165 | 23,315 | 22,765 | 18,920 | 17,501 |
| Operating Expenses | 31,898 | 29,954 | 29,864 | 27,618 | 29,013 |
| Operating Income | -4,616 | -6,513 | -6,907 | -8,054 | -11,211 |
| Interest Expense | 1,859 | 1,934 | 1,916 | 1,920 | 1,870 |
| Other Income | -3,314 | 5,955 | 1,315 | -6,530 | -4,059 |
| Pre-tax Income | -9,789 | -2,492 | -7,508 | -16,504 | -17,140 |
| Income Tax | N/A | N/A | N/A | N/A | -131 |
| Net Income Continuous | -9,789 | -2,492 | -7,508 | -16,504 | -17,009 |
| Net Income | $-9,789 | $-2,492 | $-7,508 | $-16,504 | $-17,009 |
| EPS Basic Total Ops | -0.08 | -0.02 | -0.04 | -0.14 | -0.15 |
| EPS Basic Continuous Ops | -0.10 | -0.02 | -0.05 | -0.17 | -0.18 |
| EPS Diluted Total Ops | -0.08 | -0.02 | -0.04 | -0.14 | -0.15 |
| EPS Diluted Continuous Ops | -0.10 | -0.02 | -0.05 | -0.17 | -0.18 |
| EPS Diluted Before Non-Recurring Items | -0.08 | -0.02 | -0.06 | -0.14 | -0.15 |
| EBITDA(a) | $-1,522 | $-3,686 | $-4,070 | $-5,159 | $-8,277 |